Glenmark Pharmaceuticals

Shares of Glenmark Pharmaceuticals rose 4.1 per cent at Rs 1,576.75 per share on the BSE in Tuesday's intraday trade

The company also reported a 14.6 per cent rise in revenues in the European market to Rs 687.4 crore, while recording a 1.2 per cent revenue drop in the North America market

The drugmaker reported a consolidated profit of Rs 354 crore (nearly $42 million) for the quarter ended Sept. 30, compared with a loss of Rs 81.95 crore a year ago

Q2 results today, November 14: Lemon Tree Hotels, Bharat Forge, Grasim Industries, Muthoot Finance, and Medanta to post Q2FY25 earnings on Thursday

Drug firm Glenmark is recalling two products in the US due to manufacturing issues, according to the US Food and Drug Administration. New Jersey-based Glenmark Pharmaceuticals Inc, USA, a unit of Mumbai-based Glenmark Pharmaceuticals, is recalling 45,504 bottles of Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray. The company is recalling the affected lot due to "defective delivery system", the US Food and Drug Administration (USFDA) said in its latest enforcement report. "The dip tube is clogged causing the spray not to work," it added. Glenmark Pharmaceuticals Inc, USA, initiated the nationwide (US) Class II recall on September 24 this year. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The US health regulator said the drug firm is also ...

Glenmark Pharma rallied nearly 9% to Rs 1,763.90 after the US drug regulator issued Form 483 with zero observations for its formulation manufacturing facility in Aurangabad.

The drug formulations market in India is expected to grow at a CAGR of 9-10 per cent over the next decade with Jan Aushadhi outlets anticipated to emerge as a much stronger player in the country, according to Glenmark Pharmaceuticals. The domestic formulations market is estimated to be at Rs 2 lakh crore, with a growth rate of 11 per cent over the past two decades. "It is projected that the domestic formulations market will maintain a compound annual growth rate (CAGR) of 9-10 per cent over the next decade," the Mumbai-based drug maker said in its Annual Report for 2023-24. As the Trade Generics and Jan Aushadhi channels expand, it is anticipated that these channels could collectively contribute 30 per cent to the market volume in ten years, it stated. The Jan Aushadhi initiative aims to enhance access to cost-effective, unbranded generics by scaling up to 25,000 franchise pharmacies by 2026, it said. "It is estimated that Jan Aushadhi procurement could account for 3-5 per cent o

Indian benchmark indices were likley headed for a slow start on Friday, weighed down by global cues as investors awaited crucial jobs and payroll data in the US

Glenmark Pharmaceuticals has agreed to pay USD 25 million as part of a settlement with the US Department of Justice regarding a case related to the pricing of a generic drug. Glenmark Pharmaceuticals Inc, USA, a wholly-owned subsidiary of the Mumbai-based drug maker, has agreed to pay the amount in six installments over five years, with interest on the settlement amount at a rate of 4.25 per cent per annum from May 28, 2024, the company said in a late night regulatory filing on Wednesday. The Civil Division of the US Department of Justice has concluded its False Claims Act and Anti-Kickback Statute investigation in a settlement with Glenmark Pharmaceuticals Inc, USA, it said. "The settlement amount and interest on the settlement amount constitute restitution," the drug maker said. As noted, the settlement does not contain any admission of liability by the company, except to the extent already admitted by Glenmark in the August 2023 Deferred Prosecution Agreement, it added. Last ye

Drug makers Aurobindo Pharma, Glenmark and FDC are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Aurobindo Pharma USA Inc -- a unit of Hyderabad-based drug major -- is recalling 240 bottles of pain-relieving medication Healthy Living Acetaminophen, Aspirin (NSAID) and caffeine tablets. As per the latest enforcement report of USFDA, the company is recalling the affected lot due to "Missing Label". Some bottles are missing the manufacturer's label that includes the drug facts information, the US health regulator said. The New Jersey-based Aurobindo Pharma USA Inc initiated the Class 1 recall on July 11, it said. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling 2,404 bottles of Indomethacin Extended-Release Capsules, produced at a Madhya Pradesh plant, due to "Failed Dissolutio

Glenmark Pharmaceuticals on Monday said its US-based subsidiary has introduced a generic medication used for eye itching. Glenmark Therapeutics Inc, USA has launched Olopatadine Hydrochloride Ophthalmic Solution (OTC) in the US market, the Mumbai-based drug maker said in a regulatory filing. Fabio Moreno, Head of OTC Sales & Marketing, Glenmark Pharmaceuticals Inc, said the launch of Olopatadine Ophthalmic Solution (USP, 0.1 per cent), addresses a growing demand for a new supplier in this category. "This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers," Moreno said.

The rise in the share price came after the company announced that its unit, Glenmark Therapeutics Inc, USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent.

Glenmark Pharmaceuticals stock surged up to 5.68 per cent, hitting its all time high at Rs 1,576 per share on the NSE in Friday's intraday trade

The drugmaker reported consolidated profit before exceptional items and taxes of Rs 462 crore ($55 million) for the quarter ended June 30, from Rs 203 crore a year ago

Q1FY25 company results: Cosco India, Bajaj Healthcare, Reliance Infrastructure, and Coffee Day Enterprises will be releasing their quarter results on Aug 14

The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement

Shares of Glenmark Pharmaceuticals slipped 1.60 per cent at Rs 1357.30 per share on the Bombay Stock Exchange (BSE) in Thursday's early morning trade

Stocks to watch, July 11: Global rating agency Moody's has revised its outlook on Indian private sector lender Yes Bank from "stable" to "positive"

The specific price and date of the offer for sale will likely be announced in the future

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.